TY - JOUR AB - The aim of the present study was to quantify calprotectin levels using an enzyme-linked immunosorbent assay (ELISA) and a point-of-care test (POCT) in patients with inflammatory bowel disease. Overall, 113 patients with ulcerative colitis (UC; 51 men and 62 women) and 42 patients with Crohn's disease (CD; 29 men and 13 women), who were scheduled to undergo a colonoscopy, were prospectively enrolled and scored endoscopically and clinically. An additional 96 healthy, age-matched subjects served as the normal controls. Feces and blood samples from the patients with UC and CD, and the normal controls were analyzed. These patients had received adequate medical treatment. The tissue distribution of calprotectin was investigated using immunohistochemistry. The fecal calprotectin levels, as measured using an ELISA, were correlated with the endoscopic and clinical disease activities and laboratory parameters, including serum levels of hemoglobin (Hb), albumin and C-reactive protein, and erythrocyte sedimentation rate, particularly among the patients with UC. The fecal Hb level was close to that of the fecal calprotectin level (r=0.57; P<0.0001). The fecal calprotectin level measured using an ELISA was well-correlated with the fecal calprotectin level measured using the POCT (r=0.81; P<0.0001), but was not correlated with the serum calprotectin level (r=0.1013; P=0.47). An immunohistochemical investigation revealed that patients with both UC and CD had higher neutrophil and monocyte/macrophage calprotectin-positive cell expression levels, compared with those in the normal controls. Fecal calprotectin was considered a reliable marker for disease activity, and the assessment of fecal calprotectin via POCT showed potential as a rapid and simple measurement in clinical settings. AD - Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan Department of Biostatistics Center, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan AU - Fukunaga,Shuhei AU - Kuwaki,Kotaro AU - Mitsuyama,Keiichi AU - Takedatsu,Hidetoshi AU - Yoshioka,Shinichiro AU - Yamasaki,Hiroshi AU - Yamauchi,Ryosuke AU - Mori,Atsushi AU - Kakuma,Tatsuyuki AU - Tsuruta,Osamu AU - Torimura,Takuji DA - 2018/01/01 DO - 10.3892/ijmm.2017.3244 EP - 118 IS - 1 JO - Int J Mol Med KW - calprotectin Crohn's disease feces inflammatory bowel disease enzyme-linked immunosorbent assay point‑of‑care test ulcerative colitis PY - 2018 SN - 1107-3756 1791-244X SP - 107 ST - Detection of calprotectin in inflammatory bowel disease: Fecal and serum levels and immunohistochemical localization T2 - International Journal of Molecular Medicine TI - Detection of calprotectin in inflammatory bowel disease: Fecal and serum levels and immunohistochemical localization UR - https://doi.org/10.3892/ijmm.2017.3244 VL - 41 ER -